Endo International plc (ENDP) is scheduled to release its second quarter 2015 results before the markets open on Monday, August 10. The Street is looking for revenues of $727.45 million, a 1.17% growth from $719 million in the same period a year earlier. As far as EPS is concerned, analysts expect Endo Int’l’s YoY profit to decrease by nearly 4% to $1.02. Meanwhile, EarningsWhisper.com reports a Q2’15 whisper number of $1.05 per share.
As a quick reminder, Endo International reported 1Q/15 EPS of $1.17, $0.11 better than the Street’s consensus estimate of $1.06. Revs came in at $714 million versus the $7144.44 million consensus.
On valuation measures, Endo International’s current year and next year EPS growth estimates stand at 5.10% and 15.50% compared to the industry growth rates of 44.50% and 117.50%, respectively. The issue has a t-12 price/sales ratio of 4.68. EPS for the same period registers at ($2.29).
ENDP shares have advanced 4.09% in the last 4 weeks while declining 3.78% in the past three months. Over the past 5 trading sessions the stock has lost 4.33%. The Dublin, Ireland-based specialty healthcare firm, which is currently valued at $17.44 billion, has a median Wall Street price target of $100.50 with a high target of $117.00.
ENDP is up 35.80% year-over-year and 16.13% year-to-date.